Medullary thyroid carcinoma (MTC) expresses CCK-2 receptors.111In-labeled DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2(DOTA-MG11), DOTA-DAsp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH2(DOTA-CCK), and99mTc-labeled N4-Gly-DGlu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2(99mTc-Demogastrin 2) are analogs developed for CCK-2 receptor-targeted scintigraphy. All 3 radiolabeled analogs were selected on the basis of their high CCK-2 receptor affinity and their good in vitro serum stability, with in vitro serum t1/2values of several hours. Radiolabeling of DOTA-peptides with111In requires a heating procedure, typically in the range of 80°-100°C up to 30 min. Following this procedure with DOTA-MG11 resulted in a >98 % incorporation of111In, however, with a radiochemical purity (RCP) of <50 %. The decrease in RCP was found to be due to oxidation of the methionine residue in the molecule. Moreover, this oxidized compound lost its CCK-2 receptor affinity. Therefore, conditions during radiolabeling were optimised: labeling of DOTA-MG11 and DOTA-CCK with111In involved 5 min heating at 80°C and led to an incorporation of111In of >98 %. In addition, all analogs were radiolabeled in the presence of quenchers to prevent radiolysis and oxidation resulting in a RCP of >90 %. All 3 radiolabeled analogs were i.v. administered to 6 MTC patients: radioactivity cleared rapidly by the kidneys, with no significant differences in the excretion pattern of the 3 radiotracers. All 3 radiolabeled analogs exhibited a low in vivo stability in patients, as revealed during analysis of blood samples, with the respective t1/2found in the order of minutes. In patient blood, the rank of radiopeptide in vivo stability was:99mTc-Demogastrin 2 (t1/210-15 min)>111In-DOTA-CCK (t1/2≈5-10 min)>111In-DOTA-MG11 (t1/2<5 min).

Additional Metadata
Keywords CCK, DOTA, Kidney uptake, Medullary thyroid carcinoma, Minigastrin, Receptor scintigraphy
Persistent URL,
Journal Nuclear Medicine and Biology
Breeman, W.A.P, Fröberg, A.C, de Blois, E, van Gameren, A, Melis, M.L, de Jong, M, … Krenning, E.P. (2008). Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. Nuclear Medicine and Biology, 35(8), 839–849. doi:10.1016/j.nucmedbio.2008.09.006